The company also signed a long-term agreement for operations and maintenance services of this project with Enrich Group, which will be commencing from the commissioning of this project. As a green initiative by Supriya Lifescience, the project will be operational in FY23-24 and will result in substantial savings in operating cost of the company.

Supriya Lifesciences is primarily engaged in manufacturing of bulk drugs and pharmaceutical chemicals.

The company's consolidated net profit declined 71% to Rs 16.86 crore on 25.3% decrease in net sales to Rs 112.17 crore in Q2 FY23 over Q2 FY22.